Savaysa

 

Topic mentions per year

Topic mentions per year

2015-2015
024620152015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
There has been a revolution in the development of effective, small-molecule anticoagulants and antiplatelet agents. Numerous… (More)
Is this relevant?
Review
2016
Review
2016
Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due… (More)
Is this relevant?
2015
2015
INTRODUCTION Atrial fi brillation (AF), the most common cardiac arrhythmia, is encountered in clinical practice with ever… (More)
  • figure 1
  • table 1
Is this relevant?
2015
2015
C hr is B jo rn be rg / sc ie nc e so ur ce alfa, each experienced a 90–96% reversal of Eliquis activity within two to five… (More)
  • table 1
Is this relevant?
Review
2015
Review
2015
Edoxaban (Lixiana, Savaysa) is an oral, direct factor Xa inhibitor which has recently been approved for use in the treatment of… (More)
Is this relevant?
Review
2015
Review
2015
OBJECTIVE To evaluate the current literature and potential clinical role of edoxaban (Savaysa) for stroke prevention in… (More)
  • table 1
  • table 2
  • table 2
Is this relevant?
2015
2015
The development of venous thromboembolism is one of the major causes of morbidity and mortality in patients with cancer. The… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
2015
2015
For decades, the basis for anticoagulation therapy has been the inhibition of enzymes at various levels of the coagulation… (More)
Is this relevant?
Review
2015
Review
2015
Anticoagulant After a period of many decades during which warfarin (Coumadin— Bristol-Myers Squibb) was the standard of treatment… (More)
Is this relevant?